Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2012

View Archived Issues

Polymorphism improves recovery after HBV infection

Studies show utility of florbenazine F18 in Parkinson's disease settings

Researchers at Piramal Life Sciences prepare new PI3Kalpha inhibitors

Siena Biotech patents new SMO receptor antagonists

Novel FPR2/ALX receptor agonists divulged by Actelion Pharmaceuticals

New myostatin-targeted antibody shows promise to treat cancer

New candidate cancer therapeutics designed at CSIR

Novel recombinant protein product prevents muscle damage in muscular dystrophy model

Boehringer Ingelheim presents novel MPGES-1 inhibitors

Phase I trial assesses ASG-5ME in castration-resistant prostate cancer

Astellas plans Japanese launch of extended-release tablet for restless legs syndrome

First EMA-approved artemisinin-based combination drug for uncomplicated malaria is available

Application filed in U.S. for Kineret in new indication

Endpoints met in pivotal trial of Vifor phosphate binder

Bayer product enters phase II/III hemophilia A study

New trial testing anti-inflammatory properties of RPL-554

BrainStorm Cell Therapeutics discloses encouraging data on ALS therapy

Tuberculosis partnership launches first screening round for new drug candidates

FDA approves first KRAS companion diagnostic test and Erbitux for new indication

Investigators identify possible new therapeutic target for osteoarthritis

Medigene grants exclusive EndoTAG-1 rights to SynCore

Epistem obtains CE-IVD registration for TB test

Uriach and Hyphens Pharma extend collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...